{"id":962118,"date":"2026-05-13T08:11:07","date_gmt":"2026-05-13T12:11:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"},"modified":"2026-05-13T08:11:07","modified_gmt":"2026-05-13T12:11:07","slug":"verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","title":{"rendered":"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WEST CHESTER, Pa., May  13, 2026  (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ.<\/p>\n<p>\n        <strong>H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, May 19, 2026<\/strong><br \/>\n        <br \/>\n        <strong>Event details:<\/strong><br \/>\n        <br \/>Date: Tuesday, May 19, 2026<br \/>Time: 1:30pm ET<br \/>Location: NASDAQ<\/p>\n<p>Participants may access a live webcast of the event by clicking the link <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YoNKJXW1A_K2-ai00FVJKWjhpnxRgOeAPb-JEs4Q5oV8oDkfJQZ5m2rJOLGoasDI4-Afv2W2ewgreftKalsS8LMsfkgfZK3dWqwyzL1cY-fz1hkIvj4tqm8C2CdsoSU6Ol7agvQDE4EOAJEty5ROmQ==\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p>The webcast can also be accessed in the Investors\/Presentations &amp; Events section of the Verrica website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yNN_kpcd3XySXz5OFhf-rqYU5mT3T0ZiSsJ2eNJDMEA4SfjGqnAJ01ihaBtsbM8W6HVTuohmqZgBb5pieNUH_Q==\" rel=\"nofollow\" target=\"_blank\">www.verrica.com<\/a>. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.<\/p>\n<p>\n        <strong>About Verrica Pharmaceuticals Inc.\u00a0<\/strong><br \/>\n        <br \/>Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica\u2019s product YCANTH<sup>\u00ae<\/sup>\u00a0(VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH<sup>\u00ae<\/sup>\u00a0(VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yNN_kpcd3XySXz5OFhf-rvIfe29xmuyLN38Rgkvrs4-zsQJWtSpvag6YcXfq6mPsJ_Q4uhf_wHnRQFnZ4X7aeCSSumJ_FFa_5UGO0Sk4fk8boGv9PlDQt_9XSc7jhsAg4VcM7DqhirRdy8N8RWfBBtrwFrq1Zgy_NmGuxEJCe7TmtbqbTIw_g8NAjLPNlBm6cgO8UR91HhgG5FGwGOQim6II0i_bRhEstO8swTZxr5e3JUbwHjxteSuLUe75r3Uy_DrM8nJyM-s5Si5r9SbhPg==\" rel=\"nofollow\" target=\"_blank\">www.verrica.com<\/a>.<\/p>\n<p>\n        <strong>FOR MORE INFORMATION, PLEASE CONTACT:<br \/><\/strong><br \/>\n        <br \/>Investors:<\/p>\n<p>\n        <strong>John J Kirby\u00a0<\/strong><br \/>\n        <br \/>Interim Chief Financial Officer\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OucestpOVThEFKZk8nJHZg80CA2bPGMwvsEsask3u-1DBs9lRC1HdZNToHinM4hg9i-nltYDgFAEji5LIyTLGbFYaFUbpuFA1tvJZQ2eMmM=\" rel=\"nofollow\" target=\"_blank\">jkirby@verrica.com<\/a><\/p>\n<p>\n        <strong>Kevin Gardner\u00a0<\/strong><br \/>\n        <br \/>LifeSci Advisors\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uhfxekfqrxTDR-_-ne4gvhE03tQVyBGTPD7az6i0J5py7AR6USUlVV4LmaQn0bkr0aLw7MHZ1voNG6nM0KZssCHH7Vg4Z2zdANuLHT-Edx7-O66dQO9ThPeVwtwEXYql\" rel=\"nofollow\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDViMTVlOTItYmEwYS00NDkzLTljMWEtODZjNTU1YTVmMjY3LTExMzIzMTktMjAyNi0wNS0xMy1lbg==\/tiny\/Verrica-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, May 19, 2026 Event details: Date: Tuesday, May 19, 2026Time: 1:30pm ETLocation: NASDAQ Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors\/Presentations &amp; Events section of the Verrica website at www.verrica.com. A replay of the webcast will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962118","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, May 19, 2026 Event details: Date: Tuesday, May 19, 2026Time: 1:30pm ETLocation: NASDAQ Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors\/Presentations &amp; Events section of the Verrica website at www.verrica.com. A replay of the webcast will be &hellip; Continue reading &quot;Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T12:11:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ\",\"datePublished\":\"2026-05-13T12:11:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\"},\"wordCount\":305,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\",\"name\":\"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg=\",\"datePublished\":\"2026-05-13T12:11:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","og_locale":"en_US","og_type":"article","og_title":"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk","og_description":"WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) &#8212; Verrica Pharmaceuticals Inc. (\u201cVerrica\u201d) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, May 19, 2026 Event details: Date: Tuesday, May 19, 2026Time: 1:30pm ETLocation: NASDAQ Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors\/Presentations &amp; Events section of the Verrica website at www.verrica.com. A replay of the webcast will be &hellip; Continue reading \"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-13T12:11:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ","datePublished":"2026-05-13T12:11:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"},"wordCount":305,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","name":"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg=","datePublished":"2026-05-13T12:11:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY5NiM3NTk5MDQyIzIxMjA3NDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verrica-pharmaceuticals-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962118"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962118\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}